Zylox-Tonbridge Announces Positive Profit Alert: Net Profit Expected to Increase by Approximately 140% Year-on-Year in FY2025, with Revenue Exceeding RMB 1.05 Billion

Hong Kong, January 29, 2026 — Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, the “Company” or “Zylox-Tonbridge”) today announced a positive profit alert for the fiscal year ended December 31, 2025 (“FY2025”).

The Company expects its full-year net profit to exceed RMB 240 million, reflecting a significant year-on-year increase of approximately 139.4%, while revenue is expected to exceed RMB 1.05 billion, representing a year-on-year increase of approximately 34.6%.

Zylox-Tonbridge stated that its strong financial performance was primarily driven by robust growth in core product sales, accelerated expansion of international business, and ongoing enhancements in operational efficiency.

During the reporting period, several key products, including the Kylin™ Flow Diverter, Neurovascular Guidewires, UltraFree® Drug-Coated PTA Balloon Catheter, and ZYLOX Swan™ Radiofrequency Ablation (RFA) Catheter, delivered strong sales performance, contributing to the Company’s notable revenue growth.

Meanwhile, the Company expanded its global business footprint. In FY2025, Zylox-Tonbridge achieved more than 100% year-on-year growth in overseas revenue, reflecting the Company’s expanding market presence across multiple international regions. By the end of 2025, the Company’s sales network spanned 83 countries and regions.

In January 2026, Zylox-Tonbridge announced a strategic investment in Optimed, a leading medical technology company specializing in minimally invasive vascular and endourology devices. The investment is intended to strengthen the Company’s presence in global markets and accelerate the international commercialization of its innovative products. By leveraging the operational synergies between its manufacturing bases in China and Germany, Zylox-Tonbridge also expects to enhance its global operations and delivery capabilities.

Alongside business scale expansion, Zylox-Tonbridge maintained a strong focus on operational efficiency. This disciplined approach supported a stable gross profit margin and further enhanced the Company’s profitability.

Looking ahead, Zylox-Tonbridge will remain committed to its mission of “Innovation for Quality Life”, continue to increase investment in medical technology, and accelerate its global expansion. The Company aims to deliver high-quality, affordable, and innovative products and solutions to patients worldwide, while enhancing its long-term value creation capabilities and delivering sustainable returns to shareholders.

About Zylox-Tonbridge

Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge”, HKEX: 2190) is a medical technology company dedicated to the innovative research and development, manufacturing and commercialization of medical devices in the field of vascular intervention. Founded in 2012, the Company is headquartered in Hangzhou, China.

As an integrated medical device company supported by in-house R&D and manufacturing capabilities, proprietary technology platforms and strong commercialization capabilities, Zylox-Tonbridge adheres to the brand philosophy of “Innovation for Quality Life”. The Company is committed to providing patients with high-quality, affordable medical devices and services, enabling more people to benefit from the improved quality of life brought by advanced medical technology.

For more information, please visit our official website at https://www.zyloxtb.com/.